<p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 从 “持有” 评级上调至 “买入” 评级。</p>
<p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
<ul>
<li>中型股奇迹：三只在五月超越销售预期的股票</li>
</ul>
<p>TMDX 还受到其他几份报告的关注。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 TransMedics Group 股票的 “持有（c）” 评级。Canaccord Genuity Group 在周二的报告中重申了 “买入” 评级，并设定了 142.00 美元的目标价。Needham &amp; Company LLC 在 8 月 25 日的报告中重申了对 TransMedics Group 股票的 “持有” 评级。Evercore ISI 在 9 月 16 日的研究报告中开始覆盖 TransMedics Group 股票。他们给予该股票 “跑赢大盘” 的评级，并设定了 155.00 美元的价格目标。最后，Stifel Nicolaus 在 9 月 4 日的研究报告中开始覆盖 TransMedics Group 股票。他们设定了 “持有” 评级和 115.00 美元的目标价。七位分析师对该股票给予了买入评级，六位分析师给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 127.18 美元。</p>
<p><strong>阅读我们关于 TransMedics Group 的最新报告</strong></p>
<h2>TransMedics Group 股票上涨 1.7%</h2>
<ul>
<li>三只医疗科技股票在 2025 年表现优异</li>
</ul>
<p>纳斯达克：TMDX 周五开盘价为 117.63 美元。TransMedics Group 的 52 周低点为 55.00 美元，52 周高点为 145.50 美元。该股票的市值为 40.1 亿美元，市盈率为 60.95，贝塔值为 2.08。公司的债务与股本比率为 1.61，速动比率为 9.17，流动比率为 9.86。公司的 50 日简单移动平均线为 116.52 美元，200 日简单移动平均线为 113.37 美元。</p>
<p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）最后一次发布季度财报是在 7 月 30 日。该公司报告本季度每股收益为 0.92 美元，超出分析师共识预期的 0.48 美元，超出幅度为 0.44 美元。TransMedics Group 的净利润率为 13.49%，股本回报率为 28.02%。该公司本季度的收入为 1.5737 亿美元，而分析师预期为 1.4664 亿美元。去年同期，该公司每股收益为 0.35 美元。与去年同期相比，该公司的收入增长了 37.7%。TransMedics Group 已设定其 2025 财年的每股收益指导。平均而言，股票分析师预计 TransMedics Group 本财年将发布 1 美元的每股收益。</p>
<h2>TransMedics Group 的机构交易</h2>
<ul>
<li>三只高增长股票，交易者热爱，投资者应关注</li>
</ul>
<p>几家机构投资者和对冲基金最近买入和卖出了该股票的股份。瑞银资产管理美国有限公司的一个独立业务部门在第一季度将其在 TransMedics Group 的持股增加了 244.7%。瑞银资产管理美国有限公司的一个独立业务部门现在拥有 3,113,082 股该公司的股票，价值 209,448,000 美元，在此期间又购买了 2,209,996 股。Geode Capital Management LLC 在第二季度将其在 TransMedics Group 的持股增加了 1.4%。Geode Capital Management LLC 现在拥有 804,650 股该公司的股票，价值 107,845,000 美元，在此期间又购买了 11,241 股。Driehaus Capital Management LLC 在第一季度将其在 TransMedics Group 的持股增加了 2.4%。Driehaus Capital Management LLC 现在拥有 778,754 股该公司的股票，价值 52,395,000 美元，在此期间又购买了 17,913 股。Marshall Wace LLP 在第二季度将其在 TransMedics Group 的持股增加了 258.7%。Marshall Wace LLP 现在拥有 546,787 股该公司的股票，价值 73,275,000 美元，在此期间又购买了 394,340 股。最后，高盛集团在第一季度将其在 TransMedics Group 的持股增加了 20.6%。高盛集团现在拥有 507,510 股该公司的股票，价值 34,145,000 美元，在此期间又购买了 86,721 股。99.67% 的股票目前由对冲基金和其他机构投资者持有。</p>
<h2>TransMedics Group 公司简介</h2>
<p>（获取免费报告）</p>
<p>TransMedics Group, Inc 是一家商业阶段的医疗技术公司，致力于为美国及国际上的终末期器官衰竭患者转变器官移植治疗。该公司提供器官护理系统（OCS），这是一种便携式器官灌注、优化和监测系统，利用其专有和定制技术在人体外复制接收器官的近生理条件。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 TransMedics Group</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>便士股票是否适合你的投资组合？</li>
<li>博通与 OpenAI 达成协议：为什么这对 AVGO 股票是一个巨大的胜利</li>
<li>纽约证券交易所和纳斯达克的区别，为什么这对投资者很重要</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 TransMedics Group 吗？</h2>
<p>在你考虑 TransMedics Group 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 TransMedics Group 并不在名单上。</p>
<p>虽然 TransMedics Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

TMDX

<p>华尔街禅将 TransMedics Group（NASDAQ:TMDX）的评级从 “持有” 上调至 “买入”。该股票获得了分析师的混合评级，其中包括七个买入评级和六个持有评级。目前，TMDX 的交易价格为 117.63 美元，市值为 40.1 亿美元，市盈率为 60.95。公司在上个季度报告的每股收益为 0.92 美元，超出预期，收入同比增长 37.7%。机构投资者持有 99.67% 的股份，显示出对公司的强烈兴趣</p>

<p>TransMedics Group (NASDAQ:TMDX - Get Free Report) was upgraded by Wall Street Zen from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a research note issued on Saturday.</p>
<div class="lb-trans"><p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）在周六发布的研究报告中被华尔街 Zen 从 “持有” 评级上调至 “买入” 评级。</p>
</div><p>Get <strong>TransMedics Group</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>TransMedics Group</strong> 的提醒：</p>
</div><ul>
<li>Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May</li>
</ul>
<div class="lb-trans"><ul>
<li>中型股奇迹：三只在五月超越销售预期的股票</li>
</ul>
</div><p>TMDX has been the subject of several other reports. Weiss Ratings reaffirmed a &#34;hold (c)&#34; rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a &#34;buy&#34; rating and set a $142.00 target price on shares of TransMedics Group in a report on Tuesday. Needham &amp; Company LLC reaffirmed a &#34;hold&#34; rating on shares of TransMedics Group in a report on Monday, August 25th. Evercore ISI assumed coverage on shares of TransMedics Group in a research note on Tuesday, September 16th. They issued an &#34;outperform&#34; rating and a $155.00 price target on the stock. Finally, Stifel Nicolaus assumed coverage on shares of TransMedics Group in a research note on Thursday, September 4th. They set a &#34;hold&#34; rating and a $115.00 target price on the stock. Seven analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $127.18.</p>
<div class="lb-trans"><p>TMDX 还受到其他几份报告的关注。Weiss Ratings 在 10 月 8 日的研究报告中重申了对 TransMedics Group 股票的 “持有（c）” 评级。Canaccord Genuity Group 在周二的报告中重申了 “买入” 评级，并设定了 142.00 美元的目标价。Needham &amp; Company LLC 在 8 月 25 日的报告中重申了对 TransMedics Group 股票的 “持有” 评级。Evercore ISI 在 9 月 16 日的研究报告中开始覆盖 TransMedics Group 股票。他们给予该股票 “跑赢大盘” 的评级，并设定了 155.00 美元的价格目标。最后，Stifel Nicolaus 在 9 月 4 日的研究报告中开始覆盖 TransMedics Group 股票。他们设定了 “持有” 评级和 115.00 美元的目标价。七位分析师对该股票给予了买入评级，六位分析师给予了持有评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “适度买入”，共识目标价为 127.18 美元。</p>
</div><p><strong>Read Our Latest Report on TransMedics Group</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 TransMedics Group 的最新报告</strong></p>
</div><h2>TransMedics Group Stock Up 1.7%</h2>
<div class="lb-trans"><h2>TransMedics Group 股票上涨 1.7%</h2>
</div><ul>
<li>3 Medical Technology Stocks Outperforming in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>三只医疗科技股票在 2025 年表现优异</li>
</ul>
</div><p>NASDAQ:TMDX opened at $117.63 on Friday. TransMedics Group has a fifty-two week low of $55.00 and a fifty-two week high of $145.50. The stock has a market capitalization of $4.01 billion, a P/E ratio of 60.95 and a beta of 2.08. The company has a debt-to-equity ratio of 1.61, a quick ratio of 9.17 and a current ratio of 9.86. The company's 50-day simple moving average is $116.52 and its 200-day simple moving average is $113.37.</p>
<div class="lb-trans"><p>纳斯达克：TMDX 周五开盘价为 117.63 美元。TransMedics Group 的 52 周低点为 55.00 美元，52 周高点为 145.50 美元。该股票的市值为 40.1 亿美元，市盈率为 60.95，贝塔值为 2.08。公司的债务与股本比率为 1.61，速动比率为 9.17，流动比率为 9.86。公司的 50 日简单移动平均线为 116.52 美元，200 日简单移动平均线为 113.37 美元。</p>
</div><p>TransMedics Group (NASDAQ:TMDX - Get Free Report) last released its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business had revenue of $157.37 million for the quarter, compared to analysts' expectations of $146.64 million. During the same period last year, the business earned $0.35 EPS. The company's revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that TransMedics Group will post 1 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>TransMedics Group（纳斯达克代码：TMDX - 获取免费报告）最后一次发布季度财报是在 7 月 30 日。该公司报告本季度每股收益为 0.92 美元，超出分析师共识预期的 0.48 美元，超出幅度为 0.44 美元。TransMedics Group 的净利润率为 13.49%，股本回报率为 28.02%。该公司本季度的收入为 1.5737 亿美元，而分析师预期为 1.4664 亿美元。去年同期，该公司每股收益为 0.35 美元。与去年同期相比，该公司的收入增长了 37.7%。TransMedics Group 已设定其 2025 财年的每股收益指导。平均而言，股票分析师预计 TransMedics Group 本财年将发布 1 美元的每股收益。</p>
</div><h2>Institutional Trading of TransMedics Group</h2>
<div class="lb-trans"><h2>TransMedics Group 的机构交易</h2>
</div><ul>
<li>3 High-Growth Stocks Traders Love and Investors Should Watch</li>
</ul>
<div class="lb-trans"><ul>
<li>三只高增长股票，交易者热爱，投资者应关注</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently bought and sold shares of the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in TransMedics Group by 244.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock valued at $209,448,000 after buying an additional 2,209,996 shares during the period. Geode Capital Management LLC raised its holdings in TransMedics Group by 1.4% in the 2nd quarter. Geode Capital Management LLC now owns 804,650 shares of the company's stock valued at $107,845,000 after buying an additional 11,241 shares during the period. Driehaus Capital Management LLC raised its holdings in TransMedics Group by 2.4% in the 1st quarter. Driehaus Capital Management LLC now owns 778,754 shares of the company's stock valued at $52,395,000 after buying an additional 17,913 shares during the period. Marshall Wace LLP increased its stake in TransMedics Group by 258.7% during the second quarter. Marshall Wace LLP now owns 546,787 shares of the company's stock worth $73,275,000 after purchasing an additional 394,340 shares during the period. Finally, Goldman Sachs Group Inc. increased its stake in TransMedics Group by 20.6% during the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company's stock worth $34,145,000 after purchasing an additional 86,721 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近买入和卖出了该股票的股份。瑞银资产管理美国有限公司的一个独立业务部门在第一季度将其在 TransMedics Group 的持股增加了 244.7%。瑞银资产管理美国有限公司的一个独立业务部门现在拥有 3,113,082 股该公司的股票，价值 209,448,000 美元，在此期间又购买了 2,209,996 股。Geode Capital Management LLC 在第二季度将其在 TransMedics Group 的持股增加了 1.4%。Geode Capital Management LLC 现在拥有 804,650 股该公司的股票，价值 107,845,000 美元，在此期间又购买了 11,241 股。Driehaus Capital Management LLC 在第一季度将其在 TransMedics Group 的持股增加了 2.4%。Driehaus Capital Management LLC 现在拥有 778,754 股该公司的股票，价值 52,395,000 美元，在此期间又购买了 17,913 股。Marshall Wace LLP 在第二季度将其在 TransMedics Group 的持股增加了 258.7%。Marshall Wace LLP 现在拥有 546,787 股该公司的股票，价值 73,275,000 美元，在此期间又购买了 394,340 股。最后，高盛集团在第一季度将其在 TransMedics Group 的持股增加了 20.6%。高盛集团现在拥有 507,510 股该公司的股票，价值 34,145,000 美元，在此期间又购买了 86,721 股。99.67% 的股票目前由对冲基金和其他机构投资者持有。</p>
</div><h2>TransMedics Group Company Profile</h2>
<div class="lb-trans"><h2>TransMedics Group 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.</p>
<div class="lb-trans"><p>TransMedics Group, Inc 是一家商业阶段的医疗技术公司，致力于为美国及国际上的终末期器官衰竭患者转变器官移植治疗。该公司提供器官护理系统（OCS），这是一种便携式器官灌注、优化和监测系统，利用其专有和定制技术在人体外复制接收器官的近生理条件。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than TransMedics Group</li>
<li>Health Care Stocks Explained: Why You Might Want to Invest</li>
<li>This AI Chip Giant Could Be the Market’s Next Big Winner</li>
<li>Are Penny Stocks a Good Fit for Your Portfolio?</li>
<li>Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock</li>
<li>How the NYSE and NASDAQ are Different, Why That Matters to Investors</li>
<li>Institutions Are Fueling CrowdStrike’s Next Leg Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 TransMedics Group</li>
<li>医疗保健股票解析：为什么你可能想要投资</li>
<li>这家 AI 芯片巨头可能是市场下一个大赢家</li>
<li>便士股票是否适合你的投资组合？</li>
<li>博通与 OpenAI 达成协议：为什么这对 AVGO 股票是一个巨大的胜利</li>
<li>纽约证券交易所和纳斯达克的区别，为什么这对投资者很重要</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE1EWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=TMDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in TransMedics Group Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 TransMedics Group 吗？</h2>
</div><p>Before you consider TransMedics Group, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 TransMedics Group 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TransMedics Group wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 TransMedics Group 并不在名单上。</p>
</div><p>While TransMedics Group currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 TransMedics Group 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

TransMedics Group（纳斯达克股票代码：TMDX）的评级在 Wall Street Zen 被上调至买入